Cyclacel has contributed to many scientific advancements.
A Phase 1/2, Open-label, Multi-center Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma. A poster presentation at the 34th EORTC-NCI-AACR Symposium 26-28 Oct 2022, Abstract 50.
Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS). Cancer 2021; doi: 10.1002/cncr.33828.
A precision medicine drug discovery pipeline identifies combined CDK2 and 9 inhibition as a novel therapeutic strategy in colorectal cancer. Mol Cancer Ther. 2020, 19: 2516-2527.
Sensitivity of oncogenic KRAS-expressing cells to CDK9 inhibition. SLAS Discovery. April 24, 2021; doi.org/10.1177/24725552211008853.
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021, 20:477-489.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin-dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). An oral presentation delivered at the 32nd EORTC/AACR/NCI Virtual Symposium 24-25 Oct 2020.
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Invest 2020; https://doi.org/10.1172/JCI134132.
Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer. Cancer Biol & Therapy 2020; https://doi.org/10.1080/15384047.2020.1818518.
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLOS One, July 9, 2020; doi.org/10.1371/journal.pone.0234103.
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020, 99:26.